Wael Yared
Chief Tech/Sci/R&D Officer bij TECAN GROUP AG
Vermogen: 1 M $ op 31-03-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Andreas Wilhelm | M | 55 | 20 jaar | |
Ulrich Kanter | M | 61 | 10 jaar | |
Martin Brändle | M | 53 | 16 jaar | |
Achim von Leoprechting | M | 56 | 11 jaar | |
Daniel Marshak | M | 67 | 6 jaar | |
Ingrid Pürgstaller | F | 44 | 4 jaar | |
Ralf Griebel | M | 52 | 4 jaar | |
Myra Eskes | F | - | 2 jaar | |
Tania Micki | F | 52 | 4 jaar | |
Erik Norström | M | 50 | 7 jaar | |
Klaus Lun | M | 52 | 11 jaar | |
Lukas Braunschweiler | M | 68 | 6 jaar | |
Christa Kreuzburg | M | 65 | 11 jaar | |
Günter Weisshaar | M | 64 | 21 jaar | |
Oliver Fetzer | M | 60 | 13 jaar | |
Karen Hübscher | M | 61 | 12 jaar | |
Matthias Gillner | M | 57 | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Guy L. Mayer | M | 72 |
VisEn Medical, Inc.
VisEn Medical, Inc. Medical/Nursing ServicesHealth Services VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas. | 3 jaar |
Markus Schmid | M | 56 | 9 jaar | |
Harry Wilcox | M | 69 |
VisEn Medical, Inc.
VisEn Medical, Inc. Medical/Nursing ServicesHealth Services VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas. | - |
Erik Walldén | M | 75 |
VisEn Medical, Inc.
VisEn Medical, Inc. Medical/Nursing ServicesHealth Services VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas. | - |
David Roy Martyr | M | 67 | 7 jaar | |
Heinrich Fischer | M | 74 | 16 jaar | |
John Ziolkowski | M | - |
VisEn Medical, Inc.
VisEn Medical, Inc. Medical/Nursing ServicesHealth Services VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas. | - |
Rudolf Eugster | M | 59 | 18 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Zwitserland | 21 | 84.00% |
Verenigde Staten | 4 | 16.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Wael Yared
- Persoonlijk netwerk